Recombinant Herpes Zoster Vaccine (Shingrix) is Most Appropriate Now
For this 48-year-old man with newly diagnosed chronic lymphocytic leukemia (CLL), the recombinant herpes zoster vaccine (RZV/Shingrix) should be administered now, before initiating any CLL-directed therapy. Meningococcal vaccines (both ACWY and B) are not indicated unless he has specific risk factors such as complement deficiency, complement inhibitor use, or asplenia 1.
Rationale for Herpes Zoster Vaccination
Timing is Critical in CLL
The optimal window for vaccination is before starting any CLL-directed therapy. CLL patients have inherent immune dysfunction that worsens significantly with treatment, particularly B-cell depleting therapies (anti-CD20 antibodies, BTK inhibitors) which are standard first-line treatments 2, 3. Vaccine responses are substantially better in treatment-naïve CLL patients compared to those recently treated 2.
Strong Guideline Support
The 2024 NCCN guidelines explicitly recommend RZV for adults ≥50 years of age and those ≥18 years at increased risk for herpes zoster 1. CLL patients are at markedly increased risk for herpes zoster due to disease-related T-cell dysfunction and treatment-induced immunosuppression 3.
Evidence of Efficacy in CLL
Recent data demonstrate that RZV produces strong immunogenicity in CLL patients, significantly boosting IgG levels even in actively treated patients 4. The vaccine showed acceptable safety with mostly mild local or low-grade systemic adverse events 4. A 2025 Cochrane review found that herpes zoster vaccines may reduce infection incidence up to 21 months post-vaccination, with high-certainty evidence of increased but manageable adverse events and moderate-certainty evidence of no increase in serious adverse events 5.
Dosing Schedule
RZV is administered as a 2-dose series, with doses given 2-6 months apart 1, 6. For patients who will benefit from a shorter schedule (such as those about to start therapy), the second dose can be given 1-2 months after the first 1.
Why Not Meningococcal Vaccines?
Meningococcal vaccines are only indicated for specific high-risk conditions that this patient does not have. According to NCCN guidelines, meningococcal vaccination (both MenACWY and serogroup B) is reserved for patients with 1:
- Persistent complement component deficiencies
- Use of complement C5 inhibitors (eculizumab, ravulizumab)
- Anatomic or functional asplenia
There is no indication that this 48-year-old with newly diagnosed CLL has any of these conditions. CLL alone does not constitute an indication for meningococcal vaccination.
Clinical Implementation Strategy
Immediate Action
- Administer first dose of RZV now, before any CLL treatment begins
- Schedule second dose for 2 months later (or up to 6 months if treatment timing allows)
- If CLL treatment must start urgently, give first RZV dose at least 2-4 weeks before therapy initiation 2
If Treatment Already Started
- For patients on B-cell depleting therapy: RZV can be given 1 month after the most recent dose 2
- Ideally delay until 6-12 months after completion of anti-CD20 therapy for optimal response, though vaccination is still recommended earlier if feasible 2
Common Pitfall to Avoid
Do not delay herpes zoster vaccination waiting for "the perfect time." The disease-related immune dysfunction in CLL means that even treatment-naïve patients have suboptimal responses compared to healthy individuals 7, 8. The best time is now, before treatment further compromises immune function.
Expected Adverse Events
Patients should be counseled that injection site reactions occur in approximately 40% of recipients (versus 13% with placebo), and systemic reactions in 10% (versus 6% with placebo) 6. These are typically mild and self-limited, occurring within 7 days of vaccination.